...
首页> 外文期刊>Journal of microbiology, immunology, and infection: Wei mian yu gan ran za zhi >Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths
【24h】

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths

机译:由于严重的急性呼吸综合征冠状病毒2(SARS-COV-2),急性呼吸疾病,急性呼吸道疾病和肺炎(SARS-COV-2):事实和神话

获取原文
获取原文并翻译 | 示例
           

摘要

Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2. Copyright (C) 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
机译:自2019年12月在武汉(Covid-19)的出现2019年(Covid-19)(以前称为2019年的冠状病毒[2019-NCOV]),这是由严重急性呼吸综合征冠状病毒2(SARS-COV-2引起的),在32个国家/地区报告了超过75,000例,导致全球2000多名死亡人员。尽管大多数Covid-19案件和死亡人士在中国报告,但谁宣布这一疫情作为第六届公共卫生应急的国际关切。 Covid-19可以作为无症状载体状态,急性呼吸道疾病和肺炎。成年人代表了最高感染率的人口;然而,新生儿,儿童和老年患者也可以被SARS-COV-2感染。此外,可能的医院感染医院感染和来自无症状载体的病毒传播。肺炎患者胸部成像最常见的发现是双侧受累的磨玻璃不透明度。与轻度病例相比,严重病例更容易成为潜在的合并症的老年患者。实际上,年龄和疾病严重程度可能与covid-19的结果相关。迄今为止,缺乏有效的治疗;然而,调查几种药剂(包括雷代肽和氯喹的疗效)的临床试验在中国正在进行中。目前,有效的感染控制干预是防止SARS-COV-2传播的唯一方法。版权所有(c)2020年,台湾微生物学协会。由elsevier taiwan llc发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号